Tuesday, 12 February 2019 07:56

CLINUVEL Vitiligo Communiqué II

Download PDF

Thursday, 07 February 2019 07:50

CLINUVEL Newsletter – February 2019

Download PDF

Thursday, 31 January 2019 08:51

Appendix 4C

Download PDF

Tuesday, 29 January 2019 08:18

Change of Director’s Interest Notice

Download PDF

Tuesday, 15 January 2019 07:05

CLINUVEL Newsletter – January 2019

Download attachments: Download PDF

Thursday, 10 January 2019 06:58

US FDA sets PDUFA date for SCENESSE®

US FDA sets PDUFA date for SCENESSE® Priority Review granted for innovative drug, PDUFA date 8 July 2019   Executive summary New Drug Application submitted in accordance with section 505(b) of the Federal Food, Drug, and Cosmetic Act, filed in accordance with 21 CFR 314.101(a) Scientific exchange between FDA and CLINUVEL continues under Priority Review […]

Wednesday, 19 December 2018 07:04

CLINUVEL Vitiligo Communiqué

Download attachments: Download PDF

Wednesday, 19 December 2018 06:50

CUV103 Singaporean Phase II vitiligo study results

Download attachments: Download PDF

Monday, 17 December 2018 03:59

CLINUVEL Newsletter – December 2018

Download attachments: Download PDF

Wednesday, 21 November 2018 11:37

Results of Meeting

Download Attachment: 20181121_ResultsofMeeting

Wednesday, 21 November 2018 10:21

Managing Director AGM Presentation

Download attachments: Download PDF

Tuesday, 20 November 2018 10:14

Chair’s Address to the Annual General Meeting

Download attachments: Download PDF

Monday, 05 November 2018 05:06

CLINUVEL Newsletter – November 2018

Download attachments: Download PDF

Wednesday, 31 October 2018 04:16

Appendix 4C

Appendix 4C Melbourne, Australia and Leatherhead, UK, 31 October 2018 CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow report for the period 01 July to 30 September 2018. All figures are […]

Monday, 29 October 2018 04:04

CLINUVEL expands Singapore laboratory facilities

CLINUVEL expands Singapore laboratory facilities Analytical capability established for follow-on innovative product lines at VALLAURIX, a fully owned subsidiary Summary • VALLAURIX laboratory expansion, addition of critical analytical methodologies • Supply chain integration as part of CLINUVEL’s commercial objectives • VALLAURIX focus on development of CUV9900, VLRX001 and OTC products • Laboratory research on topical and paediatric formulation Melbourne, […]